After yesterday’s glut of interesting new publications, we have only one significant new report today — a review article on the potential of so-called Src inhibitors in the management of metastatic, hormone-refractory disease. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: AZD0503, dasatinib, Src inhibitor | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 